Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Eisai, Shire Pharmaceuticals Group plc, The Alzheimer's Society regulatory update

The U.K.'s National Institute for Health and Clinical Excellence (NICE) amended its guidance for Alzheimer's disease

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE